Amylyx Pharmaceuticals, Inc. (AMLX) vs AtriCure, Inc. (ATRC)

A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and AtriCure, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Amylyx Pharmaceuticals, Inc. logo
AMLX
Amylyx Pharmaceuticals, Inc.
$3.09B
$27.82HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT
AtriCure, Inc. logo
ATRC
AtriCure, Inc.
$2.79B
$54.76HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT

Total return — AMLX vs ATRC

growth of $100 · dividends reinvested · last 5y
AMLX +53.7% (+9.0%/yr)ATRC -13.2% (-2.8%/yr)AMLX compounded faster over this window
050100150200Start $1002023202420252026$154$87
AMLX ATRC

AMLX vs ATRC: by the numbers

  • •AMLX is the larger company ($3.09B vs $2.79B market cap).
  • •ATRC is profitable (1.85% net margin) while AMLX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricAMLXATRC
P/E ratioN/A258.06
P/S ratioN/A4.89
P/B ratio12.935.39
EV / EBITDAN/A77.38
FCF yieldN/A1.84%

Profitability

MetricAMLXATRC
Gross margin0.00%76.16%
Operating margin0.00%2.44%
Net margin0.00%1.85%
ROE-63.59%2.04%
ROIC-66.60%2.04%

Growth (annualized)

MetricAMLXATRC
Revenue CAGR (5Y)N/A18.57%
Total return CAGR (5Y)N/A-4.06%

Frequently asked

Is AMLX or ATRC more profitable?
ATRC runs the higher net margin — AMLX at 0.00% versus ATRC at 1.85%.

Go deeper

Full AMLX analysisFull ATRC analysisInteractive comparison tool

Dig into the metrics

AtriCure P/E ratioAmylyx Pharmaceuticals ROEAtriCure ROEAmylyx Pharmaceuticals operating marginAtriCure operating marginAmylyx Pharmaceuticals revenue growthAtriCure revenue growthAmylyx Pharmaceuticals free cash flowAtriCure free cash flow

Amylyx Pharmaceuticals & AtriCure appear in these rankings

Fastest Revenue Growth StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.